• 1
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Woltern J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001; 344: 78392.
  • 2
    Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 71926.
  • 3
    Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 91525.
  • 4
    Yamashita J-I, Ogawa M, Yamashita S-I, Nomura K, Kuramoto M, Saishoji T, Shin S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994; 54: 16303.
  • 5
    Ghoussoub RAD, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998; 82: 151320.
  • 6
    Tsarfaty I, Alvord WG, Resau JH, Altstock RT, Lidereau R, Bieche I, Bertrand F, Horev J, Klabansky RL, Keydar I, Vande Woude GF. Alteration of Met protooncogene product expression and prognosis in breast carcinomas. Anal Quant Cytol Histol 1999; 21: 397408.
  • 7
    Ocal IT, Dolled-Filhart M, D'Aquilla TG, Camp RL, Rimm DL. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003; 97: 18418.
  • 8
    Edakuni G, Sasatomi E, Satoh T, Tokunaga O, Miyazaki K. Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma. Pathol Int 2001; 51: 2001172.
  • 9
    Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin C-Y, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/met pathway components reveals a role for met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63: 11015.
  • 10
    Cao B, Su Y, Oskarsson M, Zhao P, Kort EJ, Fisher RJ, Wang LM, Vande Woude GF. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity. Proc Natl Acad Sci USA 2001; 98: 74438.
  • 11
    Qian C-N, Guo X, Cao B, Kort EJ, Lee CC, Chen J, Wang LM, Mai WY, Min HQ, Hong MH, Vande Woude GF, Resau JH, Teh BT. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 2002; 62: 58996.
  • 12
    Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor (HGF/SF). J Biol Chem 1999; 274: 1637786.
  • 13
    Remmele W, Stegner HE. Immunhistochemischer Nachweis von Östrogenrezeptoren (Er-ICA) im Mammakarzinomgewebe, Vorschlag zur einheitlichen Bewertung des Untersuchungsbefundes. Frauenarzt 1987; 2: 413.
  • 14
    Huntsman D, Resau JH, Klineberg E, Auersperg N. Comparison of c-Met expression in ovarian epithelial tumors and normal epithelia of the female reproductive tract by quantitative laser scan microscopy. Am J Pathol 2002; 155: 3438.
  • 15
    Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Janicke F, Höfler H, Graeff H, Schmitt M. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up. Br J Cancer 1999; 80: 41926.
  • 16
    Harbeck N, Ross J, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol 1999; 14: 66371.
  • 17
    Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? a case study of c-erB-2 as a predicitve marker in breast cancer. J Clin Oncol 2001; 19: 233456.
  • 18
    Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H. The prognostic significance of amplification and overexpression of c-Met and c-erb B-2 in human gastric carcinomas. Cancer 1999; 85: 1894902.
  • 19
    Jeffers M, Koochekpour S, Fiscella M, Sathyanarayana BK, Vande Woude GF. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. Oncogene 2000; 17: 2691700.
  • 20
    Niemann C, Brinkmann V, Spitzer E, Hartmann G, Sachs M, Naundorf H, Birchmeier W. Reconstitution of mammary gland development in vitro: requirement of c-Met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol 1998; 143: 53345.
  • 21
    Firon M, Shaharabany M, Altstock RT, Horev J, Abramovici A, Resau JH, Vande Woude GF, Tsarfaty I. Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells. Oncogene 2000; 19: 238697.